Literature DB >> 16476103

Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study.

G Walldius1, A H Aastveit, I Jungner.   

Abstract

OBJECTIVES: LDL cholesterol is a well-established risk factor for myocardial infarction, but not for stroke. The main objective of the present study was to determine if the risk of stroke is related to the balance between the proatherogenic apoB lipoprotein particles and the antiatherogenic apoA-I particles as is the case for myocardial infarction. SUBJECTS AND
DESIGN: A total of 98 722 men and 76 831 women were recruited from screening programmes. The prospective risk and the relationships between five different types of fatal strokes and the lipid fractions, apoB, apoA-I and the apoB/apoA-I ratio (automated immunoturbidimetry) were examined. The results were compared with the risks of other ischaemic and non-ischaemic fatalities.
RESULTS: Mean follow-up was 10.3 years. High apoB and low apoA-I values were significantly related to risk of stroke. The odds ratio comparing the upper 10th versus the 1st decile of the apoB/apoA-I ratio for all strokes adjusted for age, gender, total cholesterol (TC) and triglycerides (TG) was 2.07 (95% CI: 1.49-2.88), P < 0.0001. The strongest association was for ischaemic stroke. Low apoA-I was a common abnormality in all stroke subtypes including subarachnoidal and haemorrhagic strokes. In multivariate analyses the apoB/apoA-I ratio was a stronger risk predictor than total/HDL and LDL/HDL cholesterol ratios. The apoB/apoA-I ratio was linearly related to the risk of stroke although the slope was less than observed for the risk of fatal myocardial infarction. For all ischaemic events pooled together the age-, gender-, TC- and TG-adjusted odds ratio, 10th vs. 1st decile, was 3.13 (95% CI: 2.66-3.69), P < 0.0001. By contrast, there was no relationship between the apoB/apoA-I ratio and risk of cancer or any other non-ischaemic causes of death.
CONCLUSIONS: These observations link the apoB/apoA-I ratio to the risk of fatal stroke in a similar fashion as for myocardial infarction and other ischaemic events. Our findings indicate that the apoB/apoA-I ratio, which indicates the 'cholesterol balance', is a robust and specific maker of virtually all ischaemic events.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16476103     DOI: 10.1111/j.1365-2796.2005.01610.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  29 in total

1.  A study of serum apolipoprotein A1, apolipoprotein B and lipid profile in stroke.

Authors:  Shilpasree As; Savitri Sahukar; Jayaprakash Murthy; Kiran Kumar
Journal:  J Clin Diagn Res       Date:  2013-07-01

2.  Nontraditional risk factors for cardiovascular disease and visceral adiposity index among different body size phenotypes.

Authors:  T Du; J Zhang; G Yuan; M Zhang; X Zhou; Z Liu; X Sun; X Yu
Journal:  Nutr Metab Cardiovasc Dis       Date:  2014-08-07       Impact factor: 4.222

3.  Apoprotein B/Apoprotein A-1 Ratio and Mortality among Prevalent Dialysis Patients.

Authors:  Yuji Sato; Shouichi Fujimoto; Tatsunori Toida; Hideto Nakagawa; Yasuhiro Yamashita; Takashi Iwakiri; Akihiro Fukuda; Shuji Iwatsubo
Journal:  Clin J Am Soc Nephrol       Date:  2016-02-15       Impact factor: 8.237

Review 4.  HDL: to treat or not to treat?

Authors:  Angela Pirillo; Gianpaolo Tibolla; Giuseppe Danilo Norata; Alberico Luigi Catapano
Journal:  Curr Atheroscler Rep       Date:  2014-08       Impact factor: 5.113

5.  Improved cholesterol phenotype analysis by a model relating lipoprotein life cycle processes to particle size.

Authors:  Daniël B van Schalkwijk; Albert A de Graaf; Ben van Ommen; Kees van Bochove; Patrick C N Rensen; Louis M Havekes; Niek C A van de Pas; Huub C J Hoefsloot; Jan van der Greef; Andreas P Freidig
Journal:  J Lipid Res       Date:  2009-06-10       Impact factor: 5.922

6.  Novel proteins associated with risk for coronary heart disease or stroke among postmenopausal women identified by in-depth plasma proteome profiling.

Authors:  Ross L Prentice; Sophie Paczesny; Aaron Aragaki; Lynn M Amon; Lin Chen; Sharon J Pitteri; Martin McIntosh; Pei Wang; Tina Buson Busald; Judith Hsia; Rebecca D Jackson; Jacques E Rossouw; Joann E Manson; Karen Johnson; Charles Eaton; Samir M Hanash
Journal:  Genome Med       Date:  2010-07-28       Impact factor: 11.117

7.  Ischemic stroke: a cardiovascular risk equivalent? Lessons learned from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.

Authors:  David H Fitchett; Shaun G Goodman; Anatoly Langer
Journal:  Can J Cardiol       Date:  2008-09       Impact factor: 5.223

Review 8.  Dyslipidemias in the prevention of cardiovascular disease: risks and causality.

Authors:  Ian Graham; Marie-Therese Cooney; David Bradley; Alexandra Dudina; Zeljko Reiner
Journal:  Curr Cardiol Rep       Date:  2012-12       Impact factor: 2.931

9.  SPARCL: the glimmer of statins for stroke risk reduction.

Authors:  Annemarie Armani; Peter P Toth
Journal:  Curr Atheroscler Rep       Date:  2007-11       Impact factor: 5.113

10.  Apolipoprotein A-I and Paraoxonase-1 Are Potential Blood Biomarkers for Ischemic Stroke Diagnosis.

Authors:  Kyle B Walsh; Kimberly Hart; Susan Roll; Matthew Sperling; Dusten Unruh; W Sean Davidson; Christopher J Lindsell; Opeolu Adeoye
Journal:  J Stroke Cerebrovasc Dis       Date:  2016-03-16       Impact factor: 2.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.